In addition, genomic alterations in SPATA2 occur in a subset of CRC patients and are largely restricted to gene amplification (~7%) (Figure 1E), and CRC tumors harboring increased copy numbers of SPATA2 display reduced levels of T cell infiltration as inferred by TIMER (23) (Figure 1F). This evidence concerns the gene SPATA2 and colorectal carcinoma.